Presentation Time: 3:00 – 4:30 PM ET
Location: Exhibit Hall C
Publication No.: 1470
Poster Title:
Ad Statistics
Times Displayed: 22253
Times Visited: 443 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Single academic center experience with 18F-fluciclovine PET/CT in prostate cancer management
Session Title: MTA 1: Prostate Posters
Presenter: Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, FSNMMI, University of Southern California
Presentation Time: 3:00 – 4:30 PM ET
Location: Exhibit Hall C
Publication No.: 1457
Poster Title:
Clinical experience with F-18-fluciclovine (Axumin®) in prostate cancer patients with a rising PSA after primary treatment
Session Title: MTA 1: Prostate Posters
Presenter: Mitchel A. Muhleman, MD, Mount Sinai Medical Center
Presentation Time: 3:00 – 4:30 PM ET
Location: Exhibit Hall C
Publication No.: 1487
Poster Title:
18F-Fluciclovine for the restaging of patients with biochemical recurrence of prostate cancer and the correlation with PSA values: Results from a single centre
Session Title: MTA 1: Prostate Posters
Presenter: Dirk Wyndaele, MD, Catharina Hospital
Presentation Time: 3:00 – 4:30 PM ET
Location: Exhibit Hall C
Publication No.: 1460
*Note: Axumin® (fluciclovine F 18) injection is FDA-approved for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. Presentations noted by “*” are investigational studies.
Blue Earth Diagnostics invites participants at this year’s SNMMI Annual Meeting to visit the company at Exhibit Booth 607. Blue Earth Diagnostics is participating in SNMMI’s Interactive Training Showcase events on the Exhibit floor, scheduled for Sunday, June 24, 2018, and Monday, June 25, 2018 from 2 – 2:30 p.m. ET.
INDICATION
Axumin® (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.
IMPORTANT SAFETY INFORMATION
Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended.
Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available.
